Do sugar-coated proteins feed Ewing sarcoma?
A zebrafish EWSR1-FLI1 model produced CD99+ small-round-cell tumors with MAPK/ERK on; blocking heparan sulfate with Surfen reduced ERK1/2 signaling and tumorigenicity in vitro and in vivo.
Source
Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth
Study at a glance
- Design
- Animal / in-vitro — Cre-inducible human EWSR1-FLI1 zebrafish model of Ewing sarcoma plus in-vitro/in-vivo tests of the heparan sulfate antagonist Surfen
- N
- N=524 · Survival analysis in 524 EWSR1-FLI1 animals; controls included uninjected N=528, GFP N=328, Cre N=304; tumor incidence also scored in n=77 Cre-injected fish
- Population
- Wild-type zebrafish embryos/larvae expressing human EWSR1-FLI1, with supporting Ewing sarcoma cell assays
- Outcome
- SRBCT formation, MAPK/ERK activity, and whether Surfen lowers ERK signaling and tumorigenicity
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Built Cre-inducible human EWSR1-FLI1 expression in wild-type zebrafish, characterized SRBCTs and ECM/heparan sulfate metabolism, then treated with the heparan sulfate antagonist Surfen in cells and fish.
What they found
EWSR1-FLI1 caused rapid, high-penetrance SRBCTs that expressed canonical targets and CD99. Tumor growth tracked MAPK/ERK activation linked to dysregulated ECM and HSPG catabolism. Surfen reduced ERK1/2 signaling and decreased tumorigenicity. Survival analysis used 524 EWSR1-FLI1 animals vs large control groups.
The limits
What it doesn't show
A zebrafish/cell study cannot yet show that Surfen is a safe human therapy; Ewing remains without an approved molecularly targeted drug from this paper alone.
Key terms
- EWSR1-FLI1
- Most common Ewing sarcoma fusion oncogene, inducibly expressed here in zebrafish.
- SRBCT
- Small round blue cell tumor histology characteristic of Ewing sarcoma.
- Heparan sulfate proteoglycans
- ECM/cell-surface glycoproteins whose catabolism was linked to ERK-driven tumor growth.
- Surfen
- Small-molecule heparan sulfate antagonist that lowered ERK1/2 and tumorigenicity.
- MAPK/ERK
- Growth signaling pathway activated in the EWSR1-FLI1 tumors.
- CD99
- Diagnostic Ewing sarcoma surface marker expressed by the zebrafish tumors.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
The fusion oncogene was:
Common questions
What animal model?
Cre-inducible human EWSR1-FLI1 in wild-type zebrafish.
What tumors formed?
High-penetrance SRBCTs expressing EWSR1-FLI1 targets and CD99.
Which pathway was on?
MAPK/ERK, tied to HSPG/ECM metabolism.
What did Surfen do?
Reduced ERK1/2 signaling and tumorigenicity in vitro and in vivo.
More on Metabolism